The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | The current challenges and unmet needs in myelofibrosis: clinical practice and trials
Claire Harrison, MD, FRCP, FRCPath, Guy’s & St Thomas’ NHS Foundation Trust, London, UK, comments on a recent paper that aims to shed light on the current challenges and unmet needs in myelofibrosis (MF), highlighting gaps in the field and areas where a change in approach is needed. Prof. Harrison emphasizes that patients should be treated earlier in the disease course and that the clinical endpoints and inclusivity of clinical trials must be improved. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Celgene, Constellation, Novartis; Advisory role: AbbVie, AOP, BMS, Celgene, CTI, Novartis, Galacteo, Geron, Gilead, Janssen, Keros, Promedior, Roche, Shire, Sierra.
